News & Press
New Drugs Improve Options for Melanoma Patients
On Wednesday, May 29, 2013, the FDA approved two new drugs for metastatic melanoma, a BRAF inhibitor and a MEK inhibitor. Liz Szabo, reporter for USA TODAY, interviewed the MRF's Executive Director, Tim Turnham, and Dr. Lynn Schuchter, Chief of Hematology Oncology at Penn Medicine and MRF Board member.
Click here for the article, "New Drugs Improve Options for Melanoma Patients."